KalVista Pharmaceuticals, Inc. (KALV) Presents at Jefferies London Healthcare Conference 2025 Transcript

Company Overview - KalVista Pharmaceuticals is a commercial pharmaceuticals company that recently received FDA approval for its first product, EKTERLY, which has been launched for the on-demand treatment of acute attacks of Hereditary Angioedema (HAE) [2] - EKTERLY is now approved in the U.S. and multiple other countries, marking a significant advancement in the treatment of HAE, a genetically driven disease characterized by episodic bouts of severe swelling [2][3] Product Innovation - EKTERLY represents a critical innovation as it allows patients to treat HAE using an oral therapy for the first time, differentiating it from existing therapies that are available [3]